|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRFAP1 |
Gene summary for MRFAP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRFAP1 | Gene ID | 93621 |
| Gene name | Morf4 family associated protein 1 | |
| Gene Alias | PAM14 | |
| Cytomap | 4p16.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9Y605 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 93621 | MRFAP1 | P31T-E | Human | Esophagus | ESCC | 7.07e-36 | 9.24e-01 | 0.1251 |
| 93621 | MRFAP1 | P32T-E | Human | Esophagus | ESCC | 9.28e-46 | 1.25e+00 | 0.1666 |
| 93621 | MRFAP1 | P36T-E | Human | Esophagus | ESCC | 2.23e-11 | 7.13e-01 | 0.1187 |
| 93621 | MRFAP1 | P37T-E | Human | Esophagus | ESCC | 1.47e-28 | 1.01e+00 | 0.1371 |
| 93621 | MRFAP1 | P38T-E | Human | Esophagus | ESCC | 1.41e-03 | 6.28e-01 | 0.127 |
| 93621 | MRFAP1 | P39T-E | Human | Esophagus | ESCC | 8.97e-14 | 2.76e-01 | 0.0894 |
| 93621 | MRFAP1 | P40T-E | Human | Esophagus | ESCC | 3.11e-10 | 3.95e-01 | 0.109 |
| 93621 | MRFAP1 | P42T-E | Human | Esophagus | ESCC | 7.00e-19 | 4.25e-01 | 0.1175 |
| 93621 | MRFAP1 | P44T-E | Human | Esophagus | ESCC | 1.48e-06 | 3.49e-01 | 0.1096 |
| 93621 | MRFAP1 | P47T-E | Human | Esophagus | ESCC | 1.81e-10 | 5.05e-01 | 0.1067 |
| 93621 | MRFAP1 | P48T-E | Human | Esophagus | ESCC | 1.19e-09 | 5.67e-01 | 0.0959 |
| 93621 | MRFAP1 | P49T-E | Human | Esophagus | ESCC | 5.12e-13 | 1.54e+00 | 0.1768 |
| 93621 | MRFAP1 | P52T-E | Human | Esophagus | ESCC | 1.23e-12 | 8.11e-01 | 0.1555 |
| 93621 | MRFAP1 | P54T-E | Human | Esophagus | ESCC | 2.22e-08 | 4.96e-01 | 0.0975 |
| 93621 | MRFAP1 | P56T-E | Human | Esophagus | ESCC | 4.13e-08 | 1.62e+00 | 0.1613 |
| 93621 | MRFAP1 | P57T-E | Human | Esophagus | ESCC | 1.17e-17 | 5.12e-01 | 0.0926 |
| 93621 | MRFAP1 | P61T-E | Human | Esophagus | ESCC | 2.35e-05 | 4.67e-01 | 0.099 |
| 93621 | MRFAP1 | P62T-E | Human | Esophagus | ESCC | 1.37e-59 | 1.36e+00 | 0.1302 |
| 93621 | MRFAP1 | P65T-E | Human | Esophagus | ESCC | 1.98e-09 | 3.87e-01 | 0.0978 |
| 93621 | MRFAP1 | P74T-E | Human | Esophagus | ESCC | 1.10e-21 | 7.92e-01 | 0.1479 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRFAP1 | SNV | Missense_Mutation | novel | c.285N>C | p.Lys95Asn | p.K95N | Q9Y605 | protein_coding | deleterious(0.04) | benign(0.035) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| MRFAP1 | SNV | Missense_Mutation | novel | c.72N>G | p.Phe24Leu | p.F24L | Q9Y605 | protein_coding | tolerated(0.35) | benign(0.015) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRFAP1 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | Q9Y605 | protein_coding | deleterious(0.03) | benign(0.014) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| MRFAP1 | deletion | Frame_Shift_Del | c.240delN | p.His81ThrfsTer41 | p.H81Tfs*41 | Q9Y605 | protein_coding | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
| MRFAP1 | SNV | Missense_Mutation | c.334G>C | p.Glu112Gln | p.E112Q | Q9Y605 | protein_coding | tolerated(0.07) | possibly_damaging(0.866) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MRFAP1 | SNV | Missense_Mutation | rs141440565 | c.313A>G | p.Lys105Glu | p.K105E | Q9Y605 | protein_coding | tolerated(0.23) | benign(0.01) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRFAP1 | SNV | Missense_Mutation | c.71N>C | p.Phe24Ser | p.F24S | Q9Y605 | protein_coding | deleterious(0.02) | possibly_damaging(0.855) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRFAP1 | SNV | Missense_Mutation | c.181G>A | p.Asp61Asn | p.D61N | Q9Y605 | protein_coding | tolerated(0.1) | possibly_damaging(0.752) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRFAP1 | SNV | Missense_Mutation | novel | c.225N>T | p.Glu75Asp | p.E75D | Q9Y605 | protein_coding | deleterious(0.02) | possibly_damaging(0.836) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| MRFAP1 | SNV | Missense_Mutation | c.73N>C | p.Glu25Gln | p.E25Q | Q9Y605 | protein_coding | tolerated(0.06) | benign(0.112) | TCGA-PG-A914-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |